Other Events ·
California Institute for Regenerative Medicine awards $15 million grant to support Phase 2 RECLAIM-LN trial of FT819
FATEFate Therapeutics Inc
On September 25, 2026, the California Institute for Regenerative Medicine awarded Fate Therapeutics a $15 million grant to support its Phase 2 RECLAIM-LN clinical trial of FT819. The award is part of CIRM's competitive CLIN2 program and funds the potentially registrational study evaluating the safety and efficacy of the off-the-shelf CAR T-cell therapy in patients with refractory lupus nephritis. This funding advances the development of a treatment designed to deplete pathological B cells for autoimmune disease management. Fate Therapeutics operates as a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies.